WAiSCH Logo
Branchenplattform
Über uns Preise Kontakt
WAiSCH
Branchen So funktioniert WAiSCH
Login
WAiSCH
Login
Firmenprofil erstellen
So funktioniert's
Über uns
Preise
Kontakt
AGB
Impressum
Datenschutz

Branchen der Industrie

Bau & Infrastruktur
Druck & Papier
Elektrotechnik
Energie & Umwelt
Holz
Kunststoff
Metall
Transport & Logistik
Verpackung

Weitere Branchen

Beauty & Gesundheit
Bekleidung & Mode
Bildung & Coaching
Blumen & Garten
Chemie & Pharma
Design & Medien
Entsorgung & Recycling
Facility Management
Ferien & Reisen
Finanzen & Versicherungen
Freizeit & Unterhaltung
Gastronomie
Hotellerie
Immobilien
Informatik & Web
Landwirtschaft
Lebensmittel
Marketing
Maschinenbau
Möbel & Einrichtung
Mobilität
Schmuck & Uhren
Sicherheit
Unternehmensberatung
  1. Luoyang Fudau Biotech Co., Ltd.
  2. News
  3. Standardized Application of Cell Factory in Vaccine Production

Standardized Application of Cell Factory in Vaccine Production

News
Kunststoff
Innovation
As one of the core systems for large-scale adherent cell culture, cell factory have become the foundation for standardized vaccine manufacturing. Their modular design, closed operation capability, and high space utilization make them an indispensable tool for both upstream virus cultivation and downstream process integration.
  • FDCELL

    FDCELL @Cell Factory with Tube

    In the modern biopharmaceutical industry, vaccine production demands high efficiency, consistent quality, and strict aseptic control. As one of the core systems for large-scale adherent cell culture, cell factory have become the foundation for standardized vaccine manufacturing. Their modular design, closed operation capability, and high space utilization make them an indispensable tool for both upstream virus cultivation and downstream process integration.

     

    1. The Role of Cell Factory in Vaccine Production

     

    Vaccines derived from adherent cell lines—such as Vero, MDCK, and BHK-21—require stable and scalable platforms for virus propagation. Traditional roller bottles or single-layer flasks are limited by manual handling and inconsistent results. In contrast, multilayer cell factories provide a controlled, reproducible environment with large surface areas (up to 25,000 cm² in a 40-layer model), allowing for efficient cell growth and high-yield virus production within a compact footprint.

     

    By minimizing open operations and enabling closed or semi-closed configurations, cell factories significantly reduce contamination risks while maintaining optimal oxygen exchange and nutrient distribution across layers.

     

    2. Standardization Across the Production Workflow

     

    Cell factory are key enablers of process standardization in vaccine production. Their consistent geometry, surface treatment, and material quality ensure batch-to-batch reproducibility—an essential requirement under GMP (Good Manufacturing Practice) conditions.

     

    Key features that support standardized manufacturing include:

     

    TC-treated growth surfaces: Promote uniform cell adhesion and monolayer formation.

    Dual large-neck design: Enhances filling and harvesting efficiency, reduces bubble formation, and facilitates gas exchange.

    Switchable vent/seal caps: Allow rapid transition between open and closed systems according to different culture stages.

    Customizable tubing assemblies: Enable integration with automated filling, perfusion, and collection systems for fully closed operation.

     

    Through these features, each production cycle can be precisely controlled, measured, and validated, ensuring consistent vaccine potency and purity.

     

    3. Integration with Automated and Closed Systems

     

    Modern vaccine production facilities increasingly adopt automated fluid handling and monitoring systems.Multilayer Cell Factory System can be seamlessly connected to peristaltic pumps, pressure systems, and sensor modules through sterile tubing assemblies. This integration transforms traditional manual operations into closed, contamination-free, and data-driven processes.

     

    When combined with automated inoculation, feeding, and harvesting equipment, FDCELL cell factory systems support continuous and scalable vaccine manufacturing, reducing labor requirements and human error while improving product traceability.

     

    4. Benefits for Biopharmaceutical Manufacturers

     

    The standardized application of cell factory provides multiple tangible benefits for vaccine manufacturers:

     

    Enhanced biosafety and aseptic assurance

    Reduced operational variability

    Lower facility and labor costs

    Simplified scale-up from lab to production

    High reproducibility and regulatory compliance

     

    These advantages make cell factory systems the ideal platform for large-scale vaccine production, supporting both traditional viral vaccines and emerging viral vector-based platforms used in gene and cell therapies.

     

    5. Outlook: Toward Fully Automated Vaccine Manufacturing

     

    As vaccine technologies evolve, the demand for modular, single-use, and automated cell culture solutions continues to grow. Cell factory, when integrated with robotics and digital control systems, represent the next step toward fully automated vaccine production lines—combining flexibility, sterility, and scalability in one standardized platform.

     

    FDCELL continues to refine and innovate its multilayer cell factory systems to meet the stringent requirements of global vaccine manufacturers. Through ISO-certified quality management, advanced TC surface treatment, and precision manufacturing in C-class cleanrooms, FDCELL provides reliable solutions that empower the future of safe, efficient, and standardized vaccine production.

    Cell Factory
    CELL-FACTORY
    Diese News wurden am Montag, 10. November 2025, von der Firma Luoyang Fudau Biotech Co., Ltd. auf WAiSCH publiziert.
    China
    Hersteller
    Luoyang Fudau Biotech Co., Ltd. - WAiSCH

    Luoyang Fudau Biotech Co., Ltd.

    471000 RM 101, 3RD BUILDING, NO.25, YUWENKAI STREET,

    Das könnte Sie ebenfalls interessieren

    • News
      Kunststoff
      Unternehmen

      INNOTEQ 2023: Nachhaltige Swissness für die MEM-Industrie

      INNOTEQ 2023: Nachhaltige Swissness für die MEM-Industrie - WAiSCH

      WAISCH Group GmbH

      Publiziert am 10. März 2023
      In diesen Tagen findet in den Hallen der BERNEXPO die INNOTEQ statt. Unser CEO berichtet live vom Branchentreffpunkt der Schweizer MEM-Industrie.
      INNOTEQ 2023: Nachhaltige Swissness für die MEM-Industrie - WAiSCH
    • News
      Kunststoff
      Medien

      Coperion: Ausbau der Partnerschaft mit Brückner

      Coperion: Ausbau der Partnerschaft mit Brückner - WAiSCH

      Kunststoff-Schweiz

      Publiziert am 21. August 2025
      Brückner Maschinenbau, weltweit führender Hersteller von Anlagen für Kunststoff-Streckfolien, beauftragt Coperion erneut mit einem Mengenkontrakt über ZSK Doppelschneckenextruder der Baureihe ZSK Mc¹⁸.
      Coperion: Ausbau der Partnerschaft mit Brückner - WAiSCH
    News der Firma Luoyang Fudau Biotech Co., Ltd.
    WAiSCH
    Wir machen Unternehmen sichtbar
    in Branchen, Suchmaschinen und KI-Systemen
    • Über uns
    • Preise
    • Firmenprofil erstellen
    • Zum Login
    • AGB
    • Impressum
    • Datenschutz
    • Kontakt
    swissmadesoftware
    • © 2026 WAiSCH
    • WAISCH Group GmbH
    • Alle Rechte vorbehalten